Overview
The primary objective is to evaluate the concordance of FDG PET/CT and total body DWI MRI sequences performed during staging and at the completion of therapy. Specifically, we will assess the positivity rates, both patient-based and lesion-based (total and by district), of the two methods during staging and at the completion of therapy. An interim analysis will be conducted comparing the two methods, followed by a final prognostic analysis.
Eligibility
Inclusion Criteria:
- • Patients with symptomatic myeloma in the staging phase or with suspected
symptomatic myeloma in the diagnostic phase
- Patients who have signed the informed consent form
Exclusion Criteria:
- Patients simultaneously affected by other neoplastic diseases or with a history of
other neoplasms in the previous 5 years
- Age < 18 years
- Women who are breastfeeding or pregnant
- Patients with metal implants or devices that constitute an absolute contraindication for MRI
- Patients with severe claustrophobia
- Patients with bone pain that prevents prolonged maintenance of the supine position